纳入标准:的临床试验
总计1170个结果
-
University Hospital FreiburgBoehringer Ingelheim终止
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; Assign Data Management and Biostatistics GmbH完全的神经内分泌癌,3 级 | 低分化恶性神经内分泌癌 | 转为 G3 的 1 级神经内分泌癌 [分化良好的神经内分泌癌] | 转为 G3 的 2 级神经内分泌癌 [中度分化神经内分泌癌] | 神经内分泌肿瘤,3 级和疾病进展,根据实体瘤反应评估标准 (RECIST 1.1.) 衡量德国
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen Memorial Hospital... 和其他合作者完全的
-
Peregrine Eye and Laser Institute完全的
-
Targeted Therapy Technologies, LLC未知
-
Chung-Ang UniversityUlsan University Hospital; Korea University Guro Hospital; Jeju National University Hospital; Kyunghee... 和其他合作者未知
-
Lions Gate HospitalUniversity of British Columbia; Vancouver Coastal Health Research Institute完全的
-
Central Arkansas Veterans Healthcare System尚未招聘
-
SoundBite Medical Solutions, Inc.Montreal Heart Institute; ethica Clinical Research Inc.撤销
-
AusculSciences Canada Inc.Ottawa Heart Institute Research Corporation未知
-
Vinmec Research Institute of Stem Cell and Gene...Vinmec Health Care System (Vingroup Joint Stock Company)完全的
-
Universitat Internacional de Catalunya尚未招聘
-
Johns Hopkins University完全的
-
Società Italiana di Cardiologia InvasivaCordis Italy a division of Johnson & Johnson Medical SpA未知
-
SurModics, Inc.主动,不招人外周动脉疾病 | 周边血管疾病 | 股腘动脉闭塞 | 动脉疾病,外周新西兰, 美国, 比利时, 拉脱维亚, 德国, 澳大利亚, 奥地利, 捷克语, 意大利